Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KCNN4 | O15554 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | PGK2 | P07205 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2349213 | 0.79 | TSHR (0.50) | TSHRCYP1A2KCNN4ALDH1A1PTPN1 | |
| SCHEMBL15259639 | 0.75 | TSHR (0.46) | TSHRCYP1A2KCNN4ALDH1A1MAPK1 | |
| SCHEMBL11143559 | 0.74 | TSHR (0.50) | TSHRCYP1A2KCNN4ALDH1A1NPSR1 | |
| SCHEMBL160529 | 0.72 | KCNN4 (0.41) | TSHRCYP1A2KCNN4ALDH1A1PTPN1 | |
| SCHEMBL6841962 | 0.72 | TSHR (0.70) | TSHRCYP1A2KCNN4ALDH1A1PTPN1 | |
| SCHEMBL2363291 | 0.72 | TSHR (0.48) | TSHRCYP1A2KCNN4ALDH1A1PTPN1 | |
| SCHEMBL1500477 | 0.69 | TSHR (0.58) | TSHRCYP1A2KCNN4ALDH1A1PTPN1 | |
| SCHEMBL1831719 | 0.69 | TSHR (0.58) | TSHRCYP1A2KCNN4ALDH1A1PTPN1 | |
| SCHEMBL7381727 | 0.69 | TSHR (0.58) | TSHRCYP1A2KCNN4ALDH1A1PTPN1 | |
| SCHEMBL11686299 | 0.69 | TSHR (0.58) | TSHRCYP1A2KCNN4ALDH1A1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 459 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107353317-A | The oligonucleotide analogs of key and/or end group between subunit with modification | 萨勒普塔医疗公司 | 2017-11-17 | — | — | CN | claimed |
| EP-2755983-B1 | SUBSTITUTED CARBONYLOXYMETHYLPHOSPHORAMIDATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-03-15 | — | — | EP | claimed |
| US-9403863-B2 | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-08-02 | — | — | US | claimed |
| US-8779128-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2014-07-15 | — | — | US | claimed |
| EP-2576574-A2 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | Sarepta Therapeutics, Inc. (US) | 2013-04-10 | — | — | EP | claimed |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2012-03-15 | — | — | US | claimed |
| WO-2011150408-A2 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | AVI BIOPHARMA, INC. (US) | 2011-12-01 | — | — | WO | claimed |
| US-5837873-A | PROTECTED OXYDIAMINES | ABBOTT LABORATORIES (US) | 1998-11-17 | — | — | US | claimed |
| WO-2024112705-A1 | BORONIC ACID AND BORONATE COMPOSITIONS AND METHODS | ELIMA THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20240101562-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME | HOLOSMEDIC (KR) | 2024-03-28 | — | — | US | disclosed |
| US-11866515-B2 | Hemiasterlin derivatives for conjugation and therapy | SUTRO BIOPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20230139442-A1 | MODIFIED AMINO ACIDS | SUTRO BIOPHARMA, INC. | 2023-05-04 | — | — | US | disclosed |
| EP-1103300-A1 | ULTRAVIOLET IRRADIATION APPARATUS FOR PHOTOCHEMICAL REACTION AND METHOD FOR PREPARING VITAMIN D DERIVATIVE USING THE SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-05-30 | — | — | EP | disclosed |
| US-5837873-A | PROTECTED OXYDIAMINES | ABBOTT LABORATORIES (US) | 1998-11-17 | — | — | US | disclosed |
| EP-0421441-B1 | Pantothenic acid derivatives | FUJIREBIO KK (JP) | 1995-01-25 | — | — | EP | disclosed |
| EP-0633242-A1 | Heptanoate derivatives | FUJIREBIO Inc. (JP) | 1995-01-11 | — | — | EP | disclosed |
| US-5120738-A | Cardiovascular disorders | FUJIREBIO INC. (JP) | 1992-06-09 | — | — | US | disclosed |
| EP-0421441-A2 | Pantothenic acid derivatives | FUJIREBIO INC. (JP) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866515-B2 | Hemiasterlin derivatives for conjugation and therapy | CYP17A1, HSD17B7, SHBG | TSHR 1951/4885CYP1A2 776/4885KCNN4 3743/4885 |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | TSHR 2993/4885CYP1A2 4698/4885KCNN4 4778/4885 |
| US-20240101562-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME | SLC11A2, ABCC1, TSG101 | TSHR 4766/4885CYP1A2 4784/4885KCNN4 4597/4885 |
| US-20230139442-A1 | MODIFIED AMINO ACIDS | PTMS, DNPEP, ANPEP | TSHR 592/4885CYP1A2 4794/4885KCNN4 4470/4885 |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SNRPE, SMN1; SMN2, UPF1 | TSHR 721/4885CYP1A2 4789/4885KCNN4 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.